You do not have access to the full text of this article, the first page of the PDF of this article appears above.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
February 2019
Volume 7, Issue 2
Volume 7, Issue 2
A Sampling of Highlights from the Literature
Jump to section
- Article
- NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
- Induction of immunosuppressive functions and NF-κB by FLIP in monocytes
- Loss of ADAR1 in tumors overcomes resistance to immune checkpoint blockade
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- Anti-NKG2A mAb is a checkpoint inhibitor that promotes antitumor immunity by unleashing both T and NK cells
- Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
- Info & Metrics
Advertisement